{"title":"Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma.","authors":"Emirhan Harbi, Michael Aschner","doi":"10.1111/jne.70017","DOIUrl":null,"url":null,"abstract":"<p><p>Pheochromocytoma and paraganglioma (PPGL) are rare and life-threatening tumors of the adrenal medulla and extra-adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including <sup>64</sup>Cu/<sup>68</sup>Ga-DOTA-SSA, <sup>18</sup>F-FDOPA, <sup>18</sup>F-FDG, <sup>123</sup>I-MIBG, and some emerging molecular imaging agents and PRRT therapies, such as <sup>203</sup>Pb VMT-α-NET and <sup>212</sup>Pb VMT-α-NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.</p>","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":" ","pages":"e70017"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jne.70017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Pheochromocytoma and paraganglioma (PPGL) are rare and life-threatening tumors of the adrenal medulla and extra-adrenal paraganglia, respectively. Management of PPGL depends on accurate diagnosis and treatment. This review provides a very comprehensive overview of nuclear medicine in PPGL with some of our perspective views on diagnostic challenges and pitfalls, treatment, and new phase studies. It describes nuclear medicine techniques including 64Cu/68Ga-DOTA-SSA, 18F-FDOPA, 18F-FDG, 123I-MIBG, and some emerging molecular imaging agents and PRRT therapies, such as 203Pb VMT-α-NET and 212Pb VMT-α-NET targeted alpha therapy (TAT). It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.
期刊介绍：
Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field.
In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
